Department of Radiology, Changi General Hospital, 2 Simei Street 3, Singapore 529889.
Department of Radiology, Changi General Hospital, 2 Simei Street 3, Singapore 529889.
Clin Imaging. 2020 Jun;62:63-68. doi: 10.1016/j.clinimag.2020.02.002. Epub 2020 Feb 8.
To study the comparative performance of contrast-enhanced ultrasound (CEUS) and contrast-enhanced CT or MRI (CECT/MR) in evaluating liver lesions using the LI-RADS guidelines.
Retrospective analysis of radiology database from July 2010 to April 2017 revealed 228 patients who had CECT/MR and CEUS. Patients at risk of hepatocellular carcinoma (HCC), had contemporaneous CEUS and CECT/CEMR studies within 3 months and adequate follow up were included; reviewed (2 reviewers) and graded according to the 2017 CEUS and 2018 CECT/MR LI-RADS guidelines. Reference standard was multidisciplinary clinical decisions, histology or follow-up imaging.
The study cohort consisted of 45 patients with 46 lesions. HCC were significantly larger than non-malignant (mean sizes of 2.5 and 1.4 cm, respectively, p<0.001). Intraclass correlation coefficient for CEUS review (0.941) was higher than of CECT/MR review (0.643). Mean area-under-ROC curve (AUC) for CEUS (0.994) was significantly higher than of CECT/MR (0.760) for all lesions (p=0.01). For lesions scored LR-3 by CECT/MR, the AUC was significantly higher for CEUS (0.978) than CECT/MR (0.500) (p<0.001). Twenty-one (of 27) lesions, classified LR-3 or LR-4 by CECT/MR were upgraded by CEUS and 20 were found to be HCC. Six lesions that were LR-3 on both CECT/MR and CEUS were found to be non-malignant. There was good concordance for LR-5 lesions between both techniques.
CEUS is useful for reassessment of lesions with intermediate probability (LR-3) or probable for HCC (LR-4) on CECT/MR. Lesions upgraded by CEUS tend to be HCC. Lesions that remain LR-3 on CEUS tend to be non-malignant.
使用 LI-RADS 指南研究对比增强超声(CEUS)与对比增强 CT 或 MRI(CECT/MR)在评估肝脏病变中的比较性能。
回顾性分析 2010 年 7 月至 2017 年 4 月的放射学数据库,共纳入 228 例患者,这些患者均进行了 CECT/MR 和 CEUS 检查。纳入标准为:肝癌(HCC)高危患者、同期 CEUS 和 CECT/MR 研究在 3 个月内完成且具有充分的随访;由 2 位阅片者进行回顾性评估,并根据 2017 年 CEUS 和 2018 年 CECT/MR LI-RADS 指南进行分级。参考标准为多学科临床决策、组织学或随访影像学。
本研究队列包括 45 例患者的 46 个病灶。HCC 明显大于非恶性病灶(平均大小分别为 2.5cm 和 1.4cm,p<0.001)。CEUS 阅片的组内相关系数(0.941)高于 CECT/MR 阅片(0.643)。CEUS 的平均曲线下面积(AUC)(0.994)显著高于 CECT/MR(0.760),用于所有病灶(p=0.01)。对于 CECT/MR 评分 LR-3 的病灶,CEUS 的 AUC(0.978)显著高于 CECT/MR(0.500)(p<0.001)。27 个 CECT/MR 分类为 LR-3 或 LR-4 的病灶中,21 个病灶经 CEUS 重新评估为升级,其中 20 个为 HCC。CEUS 上 6 个 LR-3 病灶被证实为非恶性。两种技术对 LR-5 病灶的一致性较好。
CEUS 可用于重新评估 CECT/MR 中具有中等概率(LR-3)或可能为 HCC(LR-4)的病灶。CEUS 升级的病灶倾向于 HCC。CEUS 仍为 LR-3 的病灶倾向于为非恶性。